Patient Square Capital LP Takes $1.38 Million Position in Scholar Rock Holding Co. (NASDAQ:SRRK)

Patient Square Capital LP bought a new position in Scholar Rock Holding Co. (NASDAQ:SRRK - Free Report) in the fourth quarter, according to its most recent disclosure with the SEC. The firm bought 32,000 shares of the company's stock, valued at approximately $1,383,000. Scholar Rock comprises approximately 0.5% of Patient Square Capital LP's portfolio, making the stock its 19th biggest position.

Other hedge funds and other institutional investors have also modified their holdings of the company. GAMMA Investing LLC increased its stake in shares of Scholar Rock by 51.8% in the 4th quarter. GAMMA Investing LLC now owns 788 shares of the company's stock worth $34,000 after acquiring an additional 269 shares during the last quarter. Global Retirement Partners LLC grew its holdings in shares of Scholar Rock by 584.7% during the 4th quarter. Global Retirement Partners LLC now owns 897 shares of the company's stock worth $39,000 after purchasing an additional 766 shares during the period. Nisa Investment Advisors LLC grew its holdings in shares of Scholar Rock by 1,321.8% during the 4th quarter. Nisa Investment Advisors LLC now owns 1,109 shares of the company's stock worth $48,000 after purchasing an additional 1,031 shares during the period. Amalgamated Bank grew its holdings in shares of Scholar Rock by 30.6% during the 4th quarter. Amalgamated Bank now owns 2,643 shares of the company's stock worth $114,000 after purchasing an additional 620 shares during the period. Finally, KBC Group NV purchased a new position in shares of Scholar Rock during the 4th quarter worth $131,000. 91.08% of the stock is owned by institutional investors and hedge funds.

Scholar Rock Trading Down 0.9%

Scholar Rock stock traded down $0.28 during midday trading on Friday, reaching $30.55. 1,075,653 shares of the stock traded hands, compared to its average volume of 1,273,907. The company has a 50-day simple moving average of $31.19 and a two-hundred day simple moving average of $35.87. Scholar Rock Holding Co. has a 12-month low of $6.76 and a 12-month high of $46.98. The firm has a market cap of $2.90 billion, a PE ratio of -13.00 and a beta of 0.37. The company has a current ratio of 3.88, a quick ratio of 3.88 and a debt-to-equity ratio of 0.63.

Scholar Rock (NASDAQ:SRRK - Get Free Report) last announced its earnings results on Wednesday, May 14th. The company reported ($0.67) EPS for the quarter, missing analysts' consensus estimates of ($0.63) by ($0.04). Research analysts expect that Scholar Rock Holding Co. will post -2.42 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Separately, Wedbush reiterated an "outperform" rating and set a $50.00 price target on shares of Scholar Rock in a report on Wednesday. Six equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Scholar Rock currently has a consensus rating of "Buy" and a consensus target price of $42.67.

Insider Activity at Scholar Rock

In related news, insider Tracey Sacco sold 5,000 shares of the firm's stock in a transaction dated Friday, April 25th. The stock was sold at an average price of $32.83, for a total transaction of $164,150.00. Following the completion of the transaction, the insider now directly owns 71,750 shares in the company, valued at $2,355,552.50. This trade represents a 6.51% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Mo Qatanani sold 68,510 shares of the firm's stock in a transaction dated Wednesday, February 19th. The shares were sold at an average price of $37.40, for a total value of $2,562,274.00. Following the transaction, the insider now owns 111,084 shares of the company's stock, valued at $4,154,541.60. This trade represents a 38.15% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 255,231 shares of company stock worth $9,220,236 in the last three months. 13.30% of the stock is owned by company insiders.

Scholar Rock Profile

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.